inhalon / Home |

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Allow: / # Optimization for Google Ads Bot User-agent: AdsBot-Google-Mobile User-agent: AdsBot-Google Disallow: /_api/* Disallow: /_partials* Disallow: /pro-gallery-webapp/v1/galleries/* # Block PetalBot User-agent: PetalBot Disallow: / Sitemap: https://www.inhalon.com/sitemap.xml # Auto generated, go to SEO Tools > Robots.txt Editor to change

Meta Tags

Title	Home \|
Description	Inhalon top of page Home About Leadership Board of Directors Investors Partners Platform Technology Product Publications Pipeline News & Events Careers Contact In
Keywords	N/A

Server Information

WebSite	inhalon.com
Host IP	185.230.63.107
Location	-

Related Websites

                        Site
                        Rank
                    

More to Explore

inhalon.com Valuation

US$2,011,947

Last updated: 2023-04-27 07:21:45

inhalon.com has Semrush global rank of 5,260,728. inhalon.com has an estimated worth of US$ 2,011,947, based on its estimated Ads revenue. inhalon.com receives approximately 232,148 unique visitors each day. Its web server is located in -, with IP address 185.230.63.107. According to SiteAdvisor, inhalon.com is safe to visit.

Traffic & Worth Estimates

Purchase/Sale Value	US$2,011,947
Daily Ads Revenue	US$1,858
Monthly Ads Revenue	US$55,716
Yearly Ads Revenue	US$668,586
Daily Unique Visitors	15,477
Note: All traffic and earnings values are estimates.

DNS Records

Host	Type	TTL	Data
inhalon.com.	A	3599	IP: 185.230.63.107
inhalon.com.	A	3599	IP: 185.230.63.186
inhalon.com.	A	3599	IP: 185.230.63.171
inhalon.com.	A	3599	IP: 23.236.62.147
inhalon.com.	NS	86400	NS Record: ns1.wixdns.net.
inhalon.com.	NS	86400	NS Record: ns0.wixdns.net.
inhalon.com.	MX	3600	MX Record: 1 inhalon-com.mail.protection.outlook.com.
inhalon.com.	MX	3600	MX Record: 10 inhalon-com.mail.protection.outlook.com.
inhalon.com.	TXT	3600	TXT Record: v=spf1 include:spf.protection.outlook.com -all
inhalon.com.	TXT	3600	TXT Record: MS=ms73076635

HtmlToTextCheckTime:2023-04-27 07:21:45

top of page Home About Leadership Board of Directors Investors Partners Platform Technology Product Publications Pipeline News & Events Careers Contact Inhalon Biopharma Inhaled Immunotherapy for Acute Respiratory Infections Latest News October 7, 2021 Inhalon Doses First Patient in Phase 1 Study of Inhaled IN‑006 to Treat COVID-19 Read more July 22, 2021 Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home Read more July 16, 2021 Inhalon Biopharma Appoints Jeff Hutchins, Ph.D. as Chief Development Officer Read more More Recent Publications A randomized, double-blind, Phase 1 study of IN-006, an inhaled antibody treatment for COVID-19 Moench T, Botta L, Farrer B, Lickliter JD, Kang H, Park Y, Kim C, Hoke M, Brennan M, McSweeney M, Richardson Z, Whelan J, Cho JM, Lee SY, Faurot F, Hutchins J, Lai SK medRxiv Aug 2022. Stable nebulization and muco-trapping properties of Regdanvimab/IN-006 supports its

HTTP Headers

HTTP/1.1 301 Moved Permanently
Date: Wed, 20 Oct 2021 12:54:06 GMT
Content-Length: 0
Connection: keep-alive
location: https://www.inhalon.com/
strict-transport-security: max-age=120
Age: 71595
Server-Timing: cache;desc=hit, varnish;desc=hit, dc;desc=96
X-Seen-By: gv/XVF9HsGpk8A2KWukUzCWfEJXUOf1J0Ah0dFlolkk=,sHU62EDOGnH2FBkJkG/Wx8EeXWsWdHrhlvbxtlynkVheVPYP8rg4MXNT49siPqIm,m0j2EEknGIVUW/liY8BLLo8CJZFp5+V7VR/WYDn10bQXK4CpcIIKXm19QkScmIm+,2d58ifebGbosy5xc+FRalmbGBnkWNa1BSvIgwGFR9Z/1wDXkl5bLKy+DKaRbTi+YahMrpa+SrV5ssxzL/wcvtA==,2UNV7KOq4oGjA5+PKsX47KDzNxuUDEAOOfLloEmnHbZYgeUJqUXtid+86vZww+nL
Cache-Control: no-cache
X-Wix-Request-Id: 1634734446.399600144155321745
X-Content-Type-Options: nosniff

HTTP/2 200 
date: Wed, 20 Oct 2021 12:54:06 GMT
content-type: text/html; charset=UTF-8
content-length: 321744
link: ; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,; rel=preconnect; crossorigin;,; rel=preconnect;,; rel=preconnect; crossorigin;,
etag: W/"606bc519ccdd23042da70c00833354f6"
content-language: en-US
strict-transport-security: max-age=120
age: 2902
set-cookie: ssr-caching=cache#desc=hit#varnish=hit#dc#desc=42; Max-Age=20; Expires=Wed, 20 Oct 2021 12:06:03 GMT
server-timing: cache;desc=hit, varnish;desc=hit, dc;desc=42
x-seen-by: wmgbEcS9zOENaefw7bU4YbwbN7cH/0r/4Qxj9cyhfv8=,gv/XVF9HsGpk8A2KWukUzOwfbs+7qUVAqsIx00yI78k=,sHU62EDOGnH2FBkJkG/Wx8EeXWsWdHrhlvbxtlynkViozyX1iilefXjG31S4IO7n,m0j2EEknGIVUW/liY8BLLjPDFZzqr/nlb7YyA5Dm8UkMbwluI1yUDJty9McxOlfY,2d58ifebGbosy5xc+FRalkKgXlQkq2gluzxb+I89zb23y9loKYI2jlltWw8IetQN/YDd/z4Wok7dHEgGR2sbnA==,2UNV7KOq4oGjA5+PKsX47O2a5xgRLfGhgyjJBLXaH1ZYgeUJqUXtid+86vZww+nL
cache-control: no-cache
vary: Accept-Encoding
accept-ranges: bytes
x-wix-request-id: 1634734446.593237224073120720
x-content-type-options: nosniff
set-cookie: TS01e85bed=01f0e93131d677dcf314d42f94f27211263ca9b9329898df268694962c3d2d3ca2171495a50ab7b5efcc192bd2837bb65bb3c86eac; Path=/;SameSite=none;Secure
server: Pepyaka/1.15.10

inhalon.com Whois Information

Domain Name: INHALON.COM
Registry Domain ID: 2308721834_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.google.com
Registrar URL: http://domains.google.com
Updated Date: 2021-04-29T23:13:26Z
Creation Date: 2018-09-11T13:10:32Z
Registry Expiry Date: 2021-09-11T13:10:32Z
Registrar: Google LLC
Registrar IANA ID: 895
Registrar Abuse Contact Email: registrar-abuse@google.com
Registrar Abuse Contact Phone: +1.8772376466
Domain Status: ok https://icann.org/epp#ok
Name Server: NS0.WIXDNS.NET
Name Server: NS1.WIXDNS.NET
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-09T02:13:48Z <<<

inhalon.com valuation and analysis